CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

anakinra

Last Updated: December 23, 2020
Result type: Reports
Project Number: SR0662-000
Product Line: Reimbursement Review

Generic Name: anakinra

Brand Name: Kineret

Manufacturer: Swedish Orphan Biovitrum AB

Therapeutic Area: Still's disease

Indications: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.

Manufacturer Requested Reimbursement Criteria1: For the treatment of Still’s disease with active systemic features, in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Suspended

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 16, 2020
Call for patient/clinician input closedJanuary 15, 2021
Clarification:

- Patient input submission received from Arthritis Consumer Experts and Canadian Arthritis Patient Alliance / Arthritis Society/ Cassie and Friends

Submission receivedDecember 21, 2020
Submission acceptedJanuary 12, 2021
Review initiatedJanuary 13, 2021
Clarification:

- Submission temporarily suspended